3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasm Metastasis
1
Multiple Sclerosis, Chronic Progressive
1
Multiple Sclerosis
1
Interventions
Natalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Multiple Sclerosis, Chronic Progressive
×
Natalizumab
×
Clear all
NCT01416181
2017-09-11
ASCEND in SPMS
Biogen
Phase 3
Terminated
889 enrolled
31 charts